Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Latest story Refreshed every 5 minutes; wire stories every 15 minutesAbout this data
The stock market showed choppy, mixed weekly action. But Robinhood, Sandisk, AMD and Moderna rallied into buy areas.
Moderna has announced the pricing of an upsized offering of $2.6 billion of convertible senior notes. This follows their earlier proposed private placement of $2.0 billion of convertible senior notes.
Moderna Inc. plans to raise $2 billion from selling notes that can be exchanged for shares. The funds will be used to invest in its cancer vaccine business and to repay debt.
A late-stage trial of an mRNA cancer vaccine developed by Merck & Co. and Moderna Inc. has shown promising results, preventing melanoma from returning in patients. This breakthrough marks a significant advancement in the quest to use vaccines for cancer treatment.
Moderna experienced a significant surge, soaring 129% for the week. This remarkable increase has drawn attention in the financial markets.
Quant funds faced significant pressure following the Treasury's announcement to boost buybacks, exacerbating the turmoil in momentum trades that have been unsettled since the recent AI-related stock sell-off.
Moderna and Merck's personalized mRNA cancer vaccine has successfully lengthened recurrence-free survival when paired with Keytruda for patients with high-risk skin cancer. The phase 3 win sets the partners up to potentially seek accelerated approval.
Moderna is optimistic about its cancer vaccine technology, which is based on the same platform as its successful Covid-19 vaccines. The company believes this innovation could be a 'game-changer' in oncology treatment.
Moderna's stock experienced a significant surge as the U.S. market closed, reflecting a broader rise in stocks. This movement coincided with a retreat in long-term yields, indicating a shift in investor sentiment.
Treasury Secretary Scott Bessent surprises markets with a major boost to debt buybacks as yields hit multi-year highs.
A record surge in Moderna Inc.’s shares delivered a $5 billion blow to short sellers who had bet that the vaccine maker’s years-long slump would continue.
Moderna's cancer treatment has generated excitement among investors, presenting a potential revenue platform for the company. However, the efficacy of the treatment remains inconclusive for patients, leaving many unknowns about its effectiveness.
Moderna Stock Reached New 52-Week High: What's Happening?
Moderna CEO's Surprising Comment Gives Clues About Where Drugmaker Is Going Next
Moderna Stock Is Soaring: What's Going On?
Moderna Announces Late-Breaking Data to be Presented at ESMO Congress 2026
Moderna Stock Is Surging: What's Going On?
Moderna Stock More Than Doubled in a Month. Now Comes the Hard Part
Congresswoman Bets on Elon Musk, Warren Buffett: Here's the Latest Stock Transactions
AI & Robotics in 2026: 16 Recent Developments for Investors
Moderna (MRNA) Price Forecast: Bullish Pennant Points Toward Higher Targets
Why Moderna Stock's Cancer Vaccine Rally Sparked a Rare Sell Rating